Comparative Pharmacology
Head-to-head clinical analysis: KADIAN versus LERITINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADIAN versus LERITINE.
KADIAN vs LERITINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
LERITINE (anileridine) is a synthetic opioid analgesic that acts as a mu-opioid receptor agonist, modulating pain perception and emotional response to pain.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
Adults: 25-50 mg orally every 6 hours as needed for pain; not to exceed 200 mg/day.
None Documented
None Documented
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
2-3 hours (terminal half-life in adults; may be prolonged in hepatic impairment or elderly, dosing adjustments recommended)
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Renal (70-90% as unchanged drug and metabolites); biliary/fecal (10-30%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic